Renal disease after mitomycin c therapy

Wahid Hanna, Stephen Krauss, Rolland F. Regester, William M. Murphy

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5‐fluorouracil (5‐FU) had renal impairment 6‐11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.

Original languageEnglish (US)
Pages (from-to)2583-2588
Number of pages6
JournalCancer
Volume48
Issue number12
DOIs
StatePublished - Jan 1 1981

Fingerprint

Mitomycin
Kidney
Kidney Cortex Necrosis
Tunica Intima
Arterioles
Hemolysis
Fibrin
Vascular Diseases
Acute Kidney Injury
Thrombocytopenia
Chronic Kidney Failure
Atrophy
Hyperplasia
Gastrointestinal Tract
Anemia
Pancreas
Microscopy
Electron Microscopy
Adenocarcinoma
Thrombosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Renal disease after mitomycin c therapy. / Hanna, Wahid; Krauss, Stephen; Regester, Rolland F.; Murphy, William M.

In: Cancer, Vol. 48, No. 12, 01.01.1981, p. 2583-2588.

Research output: Contribution to journalArticle

Hanna, Wahid ; Krauss, Stephen ; Regester, Rolland F. ; Murphy, William M. / Renal disease after mitomycin c therapy. In: Cancer. 1981 ; Vol. 48, No. 12. pp. 2583-2588.
@article{8d8451fda01145de9375951ba00dcd1a,
title = "Renal disease after mitomycin c therapy",
abstract = "Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5‐fluorouracil (5‐FU) had renal impairment 6‐11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.",
author = "Wahid Hanna and Stephen Krauss and Regester, {Rolland F.} and Murphy, {William M.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19811215)48:12<2583::AID-CNCR2820481208>3.0.CO;2-6",
language = "English (US)",
volume = "48",
pages = "2583--2588",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Renal disease after mitomycin c therapy

AU - Hanna, Wahid

AU - Krauss, Stephen

AU - Regester, Rolland F.

AU - Murphy, William M.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5‐fluorouracil (5‐FU) had renal impairment 6‐11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.

AB - Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5‐fluorouracil (5‐FU) had renal impairment 6‐11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.

UR - http://www.scopus.com/inward/record.url?scp=0019865902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019865902&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19811215)48:12<2583::AID-CNCR2820481208>3.0.CO;2-6

DO - 10.1002/1097-0142(19811215)48:12<2583::AID-CNCR2820481208>3.0.CO;2-6

M3 - Article

VL - 48

SP - 2583

EP - 2588

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -